USPTO serial 88404359
MEDINCELL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 16, 2020
- Examiner
- IM, JEAN H
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MEDINCELL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stephen P. McNamara
Stephen P. McNamara ST. ONGE STEWARD JOHNSTON & REENS LLC857 Post Road, Ste 398Fairfield, CT 06824-6041United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; [ pharmaceutical preparations, namely, a drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; ] veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; [ veterinary preparations, namely, a drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; ] pharmaceutical compositions for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders [ ; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugs, sold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 31, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Aug 31, 2026 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Aug 31, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 23, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 3, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 16, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 16, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 31, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 31, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 11, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 27, 2020 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Feb 7, 2020 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jan 31, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 31, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 31, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 31, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 31, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 9, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 8, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 8, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 10, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 23, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| May 19, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 13, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| May 13, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 30, 2019 | NWAP | NEW APPLICATION ENTERED | — |